echemi logo
Product
  • Product
  • Supplier
  • Inquiry
    Home > Active Ingredient News > Drugs Articles > China has launched a "battle" against four major diseases, including cardiovascular and cerebrovascular diseases

    China has launched a "battle" against four major diseases, including cardiovascular and cerebrovascular diseases

    • Last Update: 2019-07-16
    • Source: Internet
    • Author: User
    Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com
    [pharmaceutical Station industry trends] recently, the State Council issued the opinions of the State Council on the implementation of Health China action (hereinafter referred to as the opinions), which mentioned that by 2022, the health promotion policy system will be basically established, the level of health literacy of the whole people will be steadily improved, and the promotion of healthy lifestyle will be accelerated By 2030, the health literacy level of the whole people will be greatly improved In the opinion, there are 15 special actions in three aspects One of them is to strengthen the prevention and control of major diseases, including cardiovascular and cerebrovascular diseases, cancer, chronic respiratory diseases, diabetes, infectious diseases and endemic diseases It can be seen that China will launch a "battle" against four major diseases, namely, cardiovascular and cerebrovascular diseases, cancer, chronic respiratory diseases and diabetes Cardiovascular and cerebrovascular diseases are the diseases with high incidence rate and mortality rate According to China cardiovascular report 2018, there are about 290 million cardiovascular and cerebrovascular patients in China, and since 2009, the mortality rate of cardiovascular disease in rural areas has been higher than that in urban areas The data shows that in 2016, the death rate of cardiovascular disease in rural areas was 309.33/100000, and that in urban areas was 265.11/100000 The death rate of cardiovascular disease in rural areas and urban areas was 45.5% and 43.16% respectively In recent years, the prevention and treatment of cardiovascular disease in China has achieved initial results, but still faces severe challenges In general, the prevalence and mortality of cardiovascular diseases in China are still on the rise According to the opinion, by 2022 and 2030, the mortality of cardiovascular and cerebrovascular diseases will be reduced to 209.7/100000 and below and 190.7/100000 and below respectively Therefore, it will be a major and arduous task The rapid growth of the number of patients with cardiovascular and cerebrovascular diseases has brought huge market space for related drugs The industry forecasts that China's cardiovascular disease drug market will maintain a 20% growth between 2014 and 2018, and will reach 45 billion yuan in 2018 And with the aging of China's population, the continuous promotion of medical reform, and the continuous research and development of independent original drugs, China's cardiovascular disease drugs have strong competitiveness, and the whole industry will maintain double-digit growth Cancer is one of the world's top five incurable diseases According to the cancer data released by the National Cancer Center in 2017, compared with 2012, the number of new cancer cases in China increased from 3.58 million to 3.68 million, an increase of 3% In 2017, the number of new cancer cases in the world was 14.09 million, accounting for a quarter of the world In addition, according to the report issued by IARC, the number of cancer patients in the world is "growing rapidly", with 18.1 million new cases and 9.6 million deaths in 2018 alone The industry forecasts 29 million cancer cases and 16 million deaths by 2040 At present, the 5-year survival rate of cancer patients in China is about 30%, while that in developed countries is 70% to 80% According to the opinion, by 2022 and 2030, the overall 5-year survival rate of cancer will be no less than 43.3% and 46.6% respectively According to the public data, the five-year survival rate is a statistical index used by the medical community to calculate the survival rate of cancer patients and compare the advantages and disadvantages of various treatment methods In addition, the increasing incidence rate and mortality rate of cancer are increasing in the cancer drug market According to statistics, the market size of cancer drugs in China in 2017 was 20.6 billion US dollars It is estimated that the market size will reach US $23.4 billion in 2018 and exceed US $30 billion by 2020 Chronic respiratory diseases have become the second largest disease in China, next only to cardiovascular and cerebrovascular diseases According to the report on nutrition and chronic diseases of Chinese residents (2015), the mortality rate of chronic respiratory diseases in China was 68 / 100000 in 2012 It is mentioned in the opinion that by 2022 and 2030, the mortality rate of chronic respiratory diseases among people aged 70 and under will be reduced to 9 / 100000 and 8.1/100000 and below According to the industry report, the scale of China's respiratory chemical industry in 2018 was about 57.4 billion yuan, up 7.29% from 53.5 billion yuan in 2017 The number of diabetic patients in the world has increased to 366 million China is a disaster area of diabetes, and the prevalence of diabetes in China has increased rapidly in recent years According to the data, there are about 114 million diabetics in China, and the prevalence rate is as high as 11.6% However, the awareness rate and treatment rate of the patients are relatively low, especially the blood glucose standard rate is only 15.8% According to the opinion, by 2022 and 2030, the standardized management rate of diabetic patients will reach 60% and above and 70% and above respectively With the increasing income of diabetes patients, the expansion of medical insurance system and the continuous introduction of anti diabetes innovative drugs, China's diabetes market scale has developed rapidly in recent years, with a compound growth rate of 11% In 2017, the market scale exceeded 40 billion yuan, and is expected to be close to 46 billion yuan in 18 years.
    This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

    Contact Us

    The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

    Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.